Email: [email protected]

2002–2008 Chairman of the Styrian Midwife Academy

Publications (Selected)

1. Randall, L., Xiang, Y., Matsumoto, T., Giannarelli, D., Milla, D. P., Lopez, K. A., ... & Lorusso, D. (2025). Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer. Gynecologic Oncology, 199, 88-95.
2. Egle, D., Hlauschek, D., Gampenrieder, S., Rinnerthaler, G., Singer, C., Pfeiler, G., ... & Balic, M. (2025). Abstract P2-03-30: Association of ctDNA in patients with long-term outcome of breast cancer patients undergoing neoadjuvant treatment in the randomized ABCSG 34 clinical trial. Clinical Cancer Research, 31(12_Supplement), P2-03.
3. Singer, C. F., Hlauschek, D., Pfeiler, G., Egle, D., Bartsch, R., Suppan, C., ... & Gnant, M. (2025). Abstract PS3-03: Vaccination with MUC-1-targeting tecemotide improves Survival of patients receiving neo-adjuvant chemotherapy for early breast cancer: Results from the Prospective Randomized ABCSG 34 Trial. Clinical Cancer Research, 31(12_Supplement), PS3-03.
4. Wuerstlein, R., Zahn, M. O., Baerens, D. T., Guth, D., Pluschnig, U., Göhler, T., ... & Maass, N. (2025). Treatment of HER2+/HR+ early breast cancer with neratinib: final results from a retrospective single case report retrieval project. Senologie-Zeitschrift für Mammadiagnostik und-therapie, 22(02), 79.
5. Denschlag, D., Ackermann, S., Battista, M. J., Cremer, W., Egerer, G., Fehr, M., ... & Beckmann, M. W. (2022). Sarcoma of the uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry no. 015/074, April 2021). Geburtshilfe und Frauenheilkunde, 82(12), 1337-1367.
6. Guth, D., Göhler, T., Janni, W., Vannier, C., Petru, E., & Maass, N. (2024). Treatment of HER2+/HR+ early breast cancer with neratinib: first patient cases from a retrospective single case report retrieval project. Senologie-Zeitschrift für Mammadiagnostik und-therapie, 21(02), 0021.
7. Randall, L., Sukhin, V., Colombo, N., Korach, J., Matsumoto, T., Lalondrelle, S., ... & Lorusso, D. (2024). Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer. Gynecologic Oncology, 190, S9.
8. Harter, P., Wimberger, P., Okamoto, A., Reuss, A., Lim, M. C., Rubio-Pérez, M. J., ... & Aghajanian, C. (2024). Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial. Gynecologic Oncology, 190, S65-S66.
9. Colombo, N., Biagioli, E., Harano, K., Galli, F., Hudson, E., Antill, Y., ... & Santoni, A. (2024). Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 25(9), 1135-1146.
10. Singer, C. F., Hlauschek, D., Pfeiler, G., Egle, D., Bartsch, R., Suppan, C., ... & Gnant, M. (2024). Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.
11. Lee, Y. C., Colombo, N., Harano, K., Rulli, E., Hudson, E., Lee, K. B., ... & Ginesta, M. B. (2024). 36MO Patient-reported outcomes in primary advanced or recurrent endometrial carcinoma treated with atezolizumab or placebo in combination with carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial. ESMO Open, 9.

Profile Details

https://loop.frontiersin.org/people/1267943/overview

https://www.researchgate.net/scientific-contributions/Edgar-Petru-40013018